Combined treatment of gemcitabine with indole-3-carbinol or metformin on drug efficacy in pancreatic cancer cell lines: The role of human equilibrative nucleoside transporters
Journal Title: Journal of Cancer Research & Therapy - Year 2018, Vol 6, Issue 2
Abstract
Pancreatic cancer is one of the most lethal carcinomas in the United States. In accord with the American Cancer Society pancreatic cancer is anticipated to move from the third to the second leading cause of deaths in the United States by 2020. Although the standard treatment for advanced pancreatic cancer is gemcitabine (GEM), the response rate is less than 20%. Chemoresistance is a hallmark of this cancer, and modulation of drug transporters expression has been shown to increase cancer drug efficacy. Studies have shown that human equilibrative nucleoside transporters (hENTs) expression patterns may predict GEM treatment efficacy. This study investigated whether or not GEM in combination with metformin (MET) or indole-3-carbinol (I3C) increases cytotoxicity and modulates hENT1 and hENT4. Pancreatic cancer cells from males and females were treated for 24 or 72h with GEM and/or MET or I3C. Cell viability, drug interactions, and protein and mRNA expression levels of hENTs were assessed. Treatment with GEM and/or MET or I3C showed cell line specific reductions in pancreatic cancer cell proliferation, and modulation of hENT1 and hENT4 expression. Response to GEM and MET/I3C may be dependent upon the genetic profile of the tumor and the level of expression of a specific transporter. The sensitivity of GEM could depend on the method of treatment, whether cells were pre-treated with MET or I3C, which studies, including our own, have showed that pre-treatment with I3C increased upregulation of hENT1 expression in pancreatic cancer cell lines.
Authors and Affiliations
Stancy Joseph, Word B, Lyn-Cook B
Keywords
Related Articles
- EP ID EP529733
- DOI 10.14312/2052-4994.2018-2
- Views 67
- Downloads 0
Comparing docetaxel with gemcitabine as second-line chemotherapy in patients with advanced non-small cell lung cancer: A single institute randomized phase II study
Background: Platinum-based doublet chemotherapy is the backbone of treatment in advanced non-small cell lung cancer (NSCLC) however second-line treatment options are controversial particularly in patients with borderline...
Lichenoid mucocutaneous syndrome a variant of para neoplastic pemphigus (PNP) following the treatment of follicular non-Hodgkin’s lymphoma with fludarabine
Background: Paraneoplastic pemphigus (PNP) is an autoimmune mucocutaneous disease associated with cancer. Since the original description of the condition, various publications have suggested the presence of a heterogeneo...
Diagnostic problems and immune contexture in a case of cecal medullary carcinoma
Medullary carcinoma (MC) of the colon has recently been described as a separate variant of colorectal carcinoma, associated with microsatellite instability. Despite its morphological similarities to poorly differentiated...
Transcoelomic spread and ovarian seeding during ovulation: A possible pathogenesis of Krukenberg tumor
Krukenberg tumor is a metastatic ovarian tumor with its primary site being the gastrointestinal tract. The pathogenesis of Krukenberg tumor formation is still in its hypothetical stage though the current understanding su...
Changing clinical picture of endemic Burkitt’s lymphoma with improved diagnostic technology: A systematic review
We evaluated the changes in anatomical locations of endemic Burkitt’s lymphoma (eBL) by systematic review. We compared the reports before ultrasound became a routine investigation in Burkitt’s lymphoma (BL) diagnosis wit...